Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Multicenter, Randomized, Phase Ib/II Study of E7080 (Lenvatinib) in Combination With Dacarbazine Versus Dacarbazine Alone as First Line Therapy in Patients With Stage IV Melanoma.

NCT01133977 is registered in ClinicalTrials.gov with Eisai Inc. as lead sponsor.

NCT NCT01133977
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01133977 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Multicenter, Randomized, Phase Ib/II Study of E7080 (Lenvatinib) in Combination With Dacarbazine Versus Dacarbazine Alone as First Line Therapy in Patients With Stage IV Melanoma.
Lead sponsor
Eisai Inc.
Phase
Phase 1/2
Overall status
Completed
Start date
April 30, 2010
Completion date
November 30, 2014
Enrollment
97 (actual)
Sites
27

Conditions

As the registry lists them; a condition with its own page is linked.

stage iv melanoma